Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
| Autor: | Barraclough JY; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Yu J; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Cardiology, Peking University Third Hospital, Beijing, China., Figtree GA; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, New South Wales, Australia.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Perkovic V; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia., Heerspink HJL; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia., Cannon CP; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts., Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California., Schutte AE; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia., Neal B; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; The Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.; Department of Epidemiology and Biostatistics, Imperial College London, London, UK., Arnott C; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Jun; Vol. 24 (6), pp. 1072-1083. Date of Electronic Publication: 2022 Mar 07. |
| DOI: | 10.1111/dom.14671 |
| Abstrakt: | Aim: To define the proportional and absolute benefits of the sodium-glucose co-transporter-2 inhibitor canagliflozin in patients with type 2 diabetes (T2D) with and without peripheral arterial disease (PAD). Materials and Methods: We pooled individual participant data from the CANVAS Program (n = 10 142) and CREDENCE trial (n = 4401). In this post hoc analysis, the main outcomes of interest were major adverse cardiovascular events (MACE: non-fatal myocardial infarction, non-fatal stroke or cardiovascular death), kidney outcomes, and extended major adverse limb events (MALE). Cox proportional hazards models were used to assess canagliflozin treatment effects in those with and without PAD. Absolute risk reductions per 1000 patients treated for 2.5 years were estimated using Poisson regression. Results: Of 14 543 participants, 3159 (21.7%) had PAD at baseline. In patients with PAD, canagliflozin reduced MACE (hazard ratio, 0.76; 95% confidence interval, 0.62-0.92), with similar relative benefits for other cardiovascular and kidney outcomes in participants with or without PAD at baseline (all P Conclusions: Patients with T2D and PAD derived similar relative cardiorenal benefits from canagliflozin treatment but higher absolute benefits compared with those without PAD, with no increase in extended MALE. (© 2022 John Wiley & Sons Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text